BACKGROUND: The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus placebo in treatment-experienced patients with CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1), screened using the original Trofile assay. A subset with non-R5 HIV infection entered the A4001029 trial. We retrospectively examined the performance of a genotypic tropism assay based on deep sequencing of the HIV env V3 loop in predicting virologic response to maraviroc in these trials. METHODS: V3 amplicons were prepared from 1827 screening plasma samples and sequenced on a Roche/454 GS-FLX to a depth of >3000 sequences/sample. Samples were considered non-R5 if ≥2% of their viral population scored greater than or equal to -4.75 or ≤3.5 using the PSSM(x4/R5) or geno2pheno algorithms, respectively. RESULTS: Deep sequencing identified more than twice as many maraviroc recipients as having non-R5 HIV, compared with the original Trofile. With use of genotyping, we determined that 49% of maraviroc recipients with R5 HIV at screening had a week 48 viral load <50 copies/mL versus 26% of recipients with non-R5. Corresponding percentages were 46% and 23% with screening by Trofile. In cases in which screening assays differed, median week 8 log₁₀ copies/mL viral load decrease favored 454. Other parameters predicted by genotyping included likelihood of changing to non-R5 tropism. CONCLUSIONS: This large study establishes deep V3 sequencing as a promising tool for identifying treatment-experienced individuals who could benefit from CCR5-antagonist-containing regimens.
BACKGROUND: The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus placebo in treatment-experienced patients with CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1), screened using the original Trofile assay. A subset with non-R5 HIV infection entered the A4001029 trial. We retrospectively examined the performance of a genotypic tropism assay based on deep sequencing of the HIV env V3 loop in predicting virologic response to maraviroc in these trials. METHODS: V3 amplicons were prepared from 1827 screening plasma samples and sequenced on a Roche/454 GS-FLX to a depth of >3000 sequences/sample. Samples were considered non-R5 if ≥2% of their viral population scored greater than or equal to -4.75 or ≤3.5 using the PSSM(x4/R5) or geno2pheno algorithms, respectively. RESULTS: Deep sequencing identified more than twice as many maraviroc recipients as having non-R5 HIV, compared with the original Trofile. With use of genotyping, we determined that 49% of maraviroc recipients with R5 HIV at screening had a week 48 viral load <50 copies/mL versus 26% of recipients with non-R5. Corresponding percentages were 46% and 23% with screening by Trofile. In cases in which screening assays differed, median week 8 log₁₀ copies/mL viral load decrease favored 454. Other parameters predicted by genotyping included likelihood of changing to non-R5 tropism. CONCLUSIONS: This large study establishes deep V3 sequencing as a promising tool for identifying treatment-experienced individuals who could benefit from CCR5-antagonist-containing regimens.
Authors: Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst Journal: J Virol Date: 2006-05 Impact factor: 5.103
Authors: David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer Journal: J Infect Dis Date: 2010-03-15 Impact factor: 5.226
Authors: Alexey A Nabatov; Georgios Pollakis; Thomas Linnemann; Aletta Kliphius; Moustapha I M Chalaby; William A Paxton Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins Journal: J Virol Date: 2003-12 Impact factor: 5.103
Authors: A Gonzalez-Serna; R A McGovern; P R Harrigan; F Vidal; A F Y Poon; S Ferrando-Martinez; M A Abad; M Genebat; M Leal; E Ruiz-Mateos Journal: Antimicrob Agents Chemother Date: 2011-12-05 Impact factor: 5.191
Authors: Silvia Baroncelli; Clementina Maria Galluzzo; Liliana Elena Weimer; Maria Franca Pirillo; Anna Volpe; Alessandra Mercuri; Albertina Cavalli; Vincenzo Fragola; Laura Monno; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Raffaella Bucciardini; Marco Floridia Journal: J Antimicrob Chemother Date: 2012-02-23 Impact factor: 5.790
Authors: Richard H Liang; Theresa Mo; Winnie Dong; Guinevere Q Lee; Luke C Swenson; Rosemary M McCloskey; Conan K Woods; Chanson J Brumme; Cynthia K Y Ho; Janke Schinkel; Jeffrey B Joy; P Richard Harrigan; Art F Y Poon Journal: Nucleic Acids Res Date: 2014-05-07 Impact factor: 16.971
Authors: Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu Journal: J Clin Microbiol Date: 2013-03-13 Impact factor: 5.948